


PRODUCT INFORMATION



CEP-33779

Item No. 16732

CAS Registry No.: 1257704-57-6
Formal Name: N-[3-(4-methyl-1-piperazinyl)phenyl]-8-[4-(methylsulfonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-amine
MF: C₂₄H₂₆N₆O₂S
FW: 462.6
Purity: ≥95%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

CEP-33779 is supplied as a crystalline solid. A stock solution may be made by dissolving the CEP-33779 in the solvent of choice, which should be purged with an inert gas. CEP-33779 is soluble in organic solvent DMSO at a concentration of approximately 50 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of CEP-33779 can be prepared by directly dissolving the crystalline solid in aqueous buffers. CEP-33779 is sparingly soluble in aqueous solutions. We do not recommend storing the aqueous solution for more than one day.

Description

Janus kinases (JAKs) are non-receptor kinases that mediate signaling through cytokine receptors, often to members of the signal transducer and activator of transcription family. CEP-33779 is a potent, orally available inhibitor of JAK2 (IC₅₀ = 1.3 nM).¹ It shows 65-fold selectivity for JAK2 over JAK3.¹ In mouse models of systemic lupus erythematosus, CEP-33779 reduces the production of inflammatory cytokines, decreases splenomegaly and lymphomegaly, and extends survival.¹ It also diminishes inflammatory signaling and improves clinical scores in mice during collagen antibody-induced arthritis and collagen type II-induced arthritis.² CEP-33779 induces regression of established colorectal tumors in mice, reducing angiogenesis and proliferation of tumor cells.³

References

1. Lu, L.D., Stump, K.L., Wallace, N.H., *et al.* Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. *J. Immunol.* **187(7)**, 3840-3853 (2011).
2. Stump, K.L., Lu, L.D., Dobrzanski, P., *et al.* A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. *Arthritis Res. Ther.* **13(2)**, 1-15 (2011).
3. Seavey, M.M., Lu, L.D., Stump, K.L., *et al.* Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. *Mol. Cancer Ther.* **11(4)**, 984-993 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/20/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM